# A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

> **NCT05359081** · PHASE3 · TERMINATED · sponsor: **Sumitomo Pharma Co., Ltd.** · enrollment: 68 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SEP-363856

## Key facts

- **NCT ID:** NCT05359081
- **Lead sponsor:** Sumitomo Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-16
- **Primary completion:** 2024-03-21
- **Final completion:** 2024-03-28
- **Target enrollment:** 68 (ACTUAL)
- **Why stopped:** Due to company business strategy
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359081, "A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05359081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*